PRESS RELEASE Wolters Kluwer shareholders approve appointment ofMs. Rose Lee and Mr. Hikmet Ersek to the Supervisory Board Alphen aan den Rijn, The Netherlands — November 3, 2025 — Wolters Kluwer announces that Ms. Rose Lee and Mr. Hikmet Ersek have been appointed as Members of the Supervisory Board by an Extraordinary General Meeting of Shareholders (“EGM”) held today. The appointments are effective immediately and are for the period starting November 3, 2025, and ending after the AGM to be held in 2030. ...

BALTIMORE, Nov. 03, 2025 (GLOBE NEWSWIRE) -- MarketWise, Inc. (NASDAQ: MKTW) (“MarketWise” or “the Company”), a leading multi-brand digital subscription services platform that provides premium financial research, software, education, and tools for self-directed investors, today announced that its Board of Directors declared a quarterly cash dividend to holders of Class A common stock of $0.20 per share on October 30, 2025. A comparable distribution of $0.20 per unit has also been approved to holders of Mark ...

交易核心信息 - 康尼什金属公司计划通过安排计划将公司注册地迁至英国，该交易需在2025年12月3日举行的特别会议上获得股东批准 [1] - 特别会议将于2025年12月3日温哥华时间上午9点（伦敦时间下午5点）以纯虚拟音频电话会议形式举行 [2] - 交易完成后，康尼什英国公司将申请其普通股在伦敦证券交易所的AIM市场上市交易 [3] 交易条款与股东权益 - 根据安排协议，康尼什加拿大公司股东每持有10股将获得1股康尼什英国公司股票，零头部分向下取整 [8] - 交易完成后，股东在康尼什英国公司中所持有的利润、净资产和股息的比例权益将与交易前在康尼什加拿大公司中的权益完全相同 [5] - 公司股权奖励持有人将获得康尼什英国公司的替代奖励，其经济权益与交易前在康尼什加拿大公司持有的权益相同 [9] 交易时间表 - 收购所有已发行康尼什加拿大公司股票及相应发行康尼什英国公司新股预计于2025年12月16日左右进行 [23] - 康尼什英国公司全部已发行股本在AIM的上市预计于2025年12月18日左右完成 [23] - 康尼什加拿大公司股票预计于2025年12月16日从TSXV退市，并于2025年12月18日伦敦时间上午7点取消在AIM的交易 [24] 迁册原因与战略考量 - 董事会认为迁册符合公司及证券持有人的最佳利益，且根据2025年1月28日的投资协议，公司承诺在2026年3月24日前完成迁册 [6] - 鉴于公司资产所在地，英国注册公司在运营和投资者角度更为合适，多数董事将常驻英国以更贴近大部分股东、主要资产及潜在债务融资方所在地 [6] - 自2021年在AIM上市以来，公司已成功从英国资本市场融资，未来计划通过AIM上市的英国公司筹集大量新的债务和股权融资以支持增长 [6] 公司业务背景 - 康尼什金属是一家矿产勘探和开发公司，正在推进南克罗夫蒂锡矿项目投产 [25] - 南克罗夫蒂是位于英国康沃尔的历史高品位地下锡矿，拥有包括多个竖井在内的现有矿山基础设施，有效期至2071年的地下采矿许可，并可能创造超过300个直接就业岗位 [27] - 该项目将是欧洲或北美唯一的原生锡生产商，锡被英国、美国和加拿大政府定义为关键矿物 [27]

公司核心公告 - Scilex Holding Company宣布成为Dream Bowl 2026的赞助商并设定2025年11月14日为股权登记日 届时股东将获得Dream Bowl 2026 Meme Coin [1] - Meme Coin将由Datavault AI负责分发 旨在提供不可变的所有权认证和实用功能 包含票务信息、受邀运动员详情、比赛亮点等独家内容 [2] - 每持有1股普通股将获得1个Meme Coin 这些手工制作的数字币将在2025年11月25日或之后直接空投至股东在Data Vault®的钱包中 [2] 活动详情 - Dream Bowl Championship将于2026年1月11日在德克萨斯州达拉斯市的AT&T体育场举行 [3] - Datavault AI还将同期举办专业无人机竞速和电子竞技锦标赛 包括加冕《Madden Football 2026》世界冠军以及两项团队电竞赛事 [3] - 此次活动是首个将大学碗赛与电子竞技结合的活动 将汇集来自世界各地的卫冕世界冠军团队和《Madden 2026》的北美冠军 [3] Scilex公司业务概览 - Scilex是一家创收型公司 专注于收购、开发和商业化非阿片类疼痛管理产品 用于治疗急慢性疼痛、神经退行性疾病和心脏代谢疾病 [4] - 公司针对存在高度未满足需求且市场机会巨大的适应症 致力于推进和改善患者治疗效果 [4] - 已上市商业化产品包括：ZTlido®（利多卡因贴片系统1.8%）、ELYXYB®（用于急性偏头痛治疗的即用型口服溶液）、Gloperba®（用于预防痛风发作的口服液体制剂秋水仙碱） [4] Scilex产品研发管线 - 公司拥有三个在研产品候选物：SP-102（SEMDEXA®）一种用于治疗腰骶神经根性疼痛的新型粘性凝胶制剂 已完成3期临床试验并于2017年获FDA快速通道资格 [5] - SP-103是ZTlido的下一代三倍强度制剂 用于治疗急性疼痛 近期已完成针对急性腰背痛的2期试验 并已在腰背痛适应症上获得FDA快速通道资格 [5] - SP-104是一种新型低剂量延迟释放盐酸纳曲酮 正在开发用于治疗纤维肌痛 [6] 合作伙伴Datavault AI简介 - Datavault AI是AI驱动数据体验、资产估值和货币化领域的领导者 其云平台提供综合解决方案 [7] - 公司业务分为声学科学部门（拥有WiSA®、ADIO®和Sumerian®专利技术）和数据科学部门（利用高性能计算提供体验数据感知、估值和安全货币化解决方案） [7] - 其信息数据交换平台能通过将物理现实世界对象安全地连接到不可变的元数据对象 实现数字孪生和名称、形象、肖像的授权 [7]

SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Franklin Wireless Corp (FKWL) announced the JEXtream CG890, a next-generation 5G Fixed Wireless Access (FWA) router designed to deliver reliable, high-speed connectivity for service providers and community-focused organizations. The CG890 bridges the gap between enterprise-grade capability and accessible deployment. Built for versatility, the CG890 is ideal for cost-conscious consumers, small businesses, and nonprofits expanding digital equity programs, as well a ...

At 24 months, the target lesion primary patency (TLPP)1 was 41.7%At 24 months, the access circuit primary patency (ACPP)2 was 25.7% SOUTH JORDAN, Utah, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced 24-month efficacy findings from the non-randomized AVG cohort of the WAVE trial. Results of the AVG cohort were presented during the Late-Breaking Clinical Trials session at the annual VIVA Foundation3 Venous Endovascular In ...

Aspocomp Group Plc, Stock Exchange Release, November 3, 2025 at 4:20 p.m.The new shares subscribed for in Aspocomp Group Plc’s directed share issue have been registered with the Trade Register.A total of 673,682 new shares subscribed for in Aspocomp’s Directed Share Issue have been registered with the Finnish Trade Register on October 31, 2025. After the registration of the new shares, the total number of shares in the company is 7,522,922 shares. The new shares will confer equal rights to the company’s exi ...

PARAMUS, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- ALEXANDER’S, INC. (New York Stock Exchange: ALX) filed its Form 10-Q for the quarter ended September 30, 2025 today and reported: Third Quarter 2025 Financial Results Net income for the quarter ended September 30, 2025 was $6.0 million, or $1.16 per diluted share, compared to $6.7 million, or $1.30 per diluted share for the quarter ended September 30, 2024. Funds from operations (“FFO”) (non-GAAP) for the quarter ended September 30, 2025 was $14.9 million, or ...

ATHENS, Greece, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Diana Shipping Inc. (NYSE: DSX), (the “Company”), a global shipping company specializing in the ownership and bareboat charter-in of dry bulk vessels, today announced that, through a separate wholly-owned subsidiary, it has entered into a time charter contract with MOL Ocean Bulk Pte. Ltd., Singapore, for one of its Newcastlemax dry bulk vessels, the m/v Los Angeles. The gross charter rate is US$24,000, minus a 5.00% commission paid to third parties, for a p ...

Preliminary data recently shared for eti-cel (UCART20x22) show an 86% ORR and a 57% CR rate (n=7), underscoring its potential to improve outcomes in r/r NHLPreclinical data demonstrated that combining eti-cel with low-dose IL-2 may deepen and extend anti-tumor activity in patients with r/r NHLEti-cel full Phase 1 dataset, including low-dose IL-2 combination cohorts, expected to be presented in 2026Correlation between alemtuzumab exposure and response with lasme-cel (UCART22) allows optimization of efficacy ...